2022
DOI: 10.3389/fonc.2022.1027748
|View full text |Cite
|
Sign up to set email alerts
|

Analysis of exosomal competing endogenous RNA network response to paclitaxel treatment reveals key genes in advanced gastric cancer

Abstract: BackgroundExosome is an important component of the tumor immune microenvironment and plays critical role in cancer pathogenesis. The exosome transcriptome of gastric cancer (GC) response to paclitaxel chemotherapy has not been investigated in the past.MethodsceRNA microarrays were performed in exosomes from six advanced GC patients before and after paclitaxel treatment. Bioinformatics tools were used to identify differential expressing genes and construct competing endogenous RNA (ceRNA) networks. The importan… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 36 publications
0
2
0
Order By: Relevance
“…As a new fluorinated anti-metabolite, gemcitabine contributes to enhancing the individual anti-tumor activity of either 5-Fluorouracil or oxaliplatin ( Nam et al, 2013 ). Paclitaxel is a chemotherapeutic agent that has been applied to treat various types of cancer, and its monotherapy can significantly ameliorate the tumor response and prognosis of GC ( Lei et al, 2022 ). Immunotherapy and chemotherapy combined may provide precise treatment with various risk scores.…”
Section: Discussionmentioning
confidence: 99%
“…As a new fluorinated anti-metabolite, gemcitabine contributes to enhancing the individual anti-tumor activity of either 5-Fluorouracil or oxaliplatin ( Nam et al, 2013 ). Paclitaxel is a chemotherapeutic agent that has been applied to treat various types of cancer, and its monotherapy can significantly ameliorate the tumor response and prognosis of GC ( Lei et al, 2022 ). Immunotherapy and chemotherapy combined may provide precise treatment with various risk scores.…”
Section: Discussionmentioning
confidence: 99%
“…Exosome transcriptome could represent a more detailed and specific molecular biomarker compared with a single RNA type. The use of exosome transcriptome to predict the treatment response of nCRT has been widely used in other cancers (such as breast cancer and gastric cancer) (10,11); however, it is still in its infancy and has not been reported in ESCC. In addition, the current efficacy prediction mainly uses exo-miRNA panels, which cannot reveal the deep relationship between the three important types of exo-RNAs (mRNA, miRNA, and lncRNA).…”
Section: Introductionmentioning
confidence: 99%